CN121949079A - 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 - Google Patents
治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物Info
- Publication number
- CN121949079A CN121949079A CN202610035916.3A CN202610035916A CN121949079A CN 121949079 A CN121949079 A CN 121949079A CN 202610035916 A CN202610035916 A CN 202610035916A CN 121949079 A CN121949079 A CN 121949079A
- Authority
- CN
- China
- Prior art keywords
- compound
- och
- independently
- ocf
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
- C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911069P | 2019-10-04 | 2019-10-04 | |
| US62/911,069 | 2019-10-04 | ||
| US202062991525P | 2020-03-18 | 2020-03-18 | |
| US62/991,525 | 2020-03-18 | ||
| CN202080084283.6A CN114746430B (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 |
| PCT/US2020/054107 WO2021067836A1 (en) | 2019-10-04 | 2020-10-02 | Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080084283.6A Division CN114746430B (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN121949079A true CN121949079A (zh) | 2026-05-01 |
Family
ID=72964859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202610035916.3A Pending CN121949079A (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 |
| CN202080084283.6A Active CN114746430B (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080084283.6A Active CN114746430B (zh) | 2019-10-04 | 2020-10-02 | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11584728B2 (https=) |
| EP (1) | EP4038076A1 (https=) |
| JP (2) | JP2022551270A (https=) |
| KR (1) | KR20220078644A (https=) |
| CN (2) | CN121949079A (https=) |
| AU (1) | AU2020358970B2 (https=) |
| CA (1) | CA3156499A1 (https=) |
| IL (1) | IL291898A (https=) |
| WO (1) | WO2021067836A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121949079A (zh) * | 2019-10-04 | 2026-05-01 | 康德生物医疗有限公司 | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 |
| CA3222132A1 (en) * | 2021-06-10 | 2022-12-15 | Stealth Biotherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| WO2025024247A1 (en) * | 2023-07-21 | 2025-01-30 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
| WO2025101748A1 (en) * | 2023-11-09 | 2025-05-15 | Stealth Biotherapeutics Inc. | Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
| WO2026020091A1 (en) * | 2024-07-19 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compounds, compositions, formulations and uses for addressing mitochondrial disease resulting from nuclear dna mutations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| CA2272971C (en) | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| WO2005033093A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| ES2619303T3 (es) * | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| SI1933821T1 (sl) | 2005-09-15 | 2020-11-30 | Ptc Therapeutics, Inc. | Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev |
| WO2007100652A2 (en) | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP2332534B1 (en) * | 2006-02-22 | 2018-11-14 | Bioelectron Technology Corporation | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| JP5798481B2 (ja) | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NO2470168T3 (https=) | 2009-08-26 | 2018-06-30 | ||
| SG187744A1 (en) | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| EP2606022A2 (en) * | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| DK2605769T3 (en) | 2010-08-16 | 2016-10-24 | Santhera Pharmaceuticals (Schweiz) Ag | Benzoquinonderivater for the treatment of mitochondrial diseases of the eye |
| US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| KR102137450B1 (ko) * | 2012-07-12 | 2020-07-27 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체 |
| CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Ptc Therapeutics, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| CN104870432B (zh) | 2012-11-16 | 2017-05-03 | 美国健康及人类服务部 | 作为溶酶体贮积症的修复剂的生育酚和生育醌衍生物 |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| EP3377179B1 (en) * | 2015-11-19 | 2021-04-07 | Concert Pharmaceuticals Inc. | Deuterated epi-743 |
| US10703701B2 (en) * | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| WO2018191732A1 (en) * | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| ES2942631T3 (es) | 2017-12-15 | 2023-06-05 | Stealth Biotherapeutics Inc | Péptidos dirigidos a mitocondrias |
| CN121949079A (zh) * | 2019-10-04 | 2026-05-01 | 康德生物医疗有限公司 | 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物 |
-
2020
- 2020-10-02 CN CN202610035916.3A patent/CN121949079A/zh active Pending
- 2020-10-02 AU AU2020358970A patent/AU2020358970B2/en active Active
- 2020-10-02 US US17/062,339 patent/US11584728B2/en active Active
- 2020-10-02 IL IL291898A patent/IL291898A/en unknown
- 2020-10-02 CA CA3156499A patent/CA3156499A1/en active Pending
- 2020-10-02 JP JP2022520475A patent/JP2022551270A/ja active Pending
- 2020-10-02 WO PCT/US2020/054107 patent/WO2021067836A1/en not_active Ceased
- 2020-10-02 EP EP20793924.0A patent/EP4038076A1/en active Pending
- 2020-10-02 KR KR1020227014887A patent/KR20220078644A/ko active Pending
- 2020-10-02 CN CN202080084283.6A patent/CN114746430B/zh active Active
-
2022
- 2022-12-23 US US18/087,890 patent/US12049455B2/en active Active
-
2024
- 2024-07-02 US US18/761,782 patent/US20240368098A1/en active Pending
- 2024-07-02 US US18/761,854 patent/US20240400529A1/en active Pending
-
2025
- 2025-07-03 JP JP2025113088A patent/JP2025164962A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3156499A1 (en) | 2021-04-08 |
| US12049455B2 (en) | 2024-07-30 |
| US20210206736A1 (en) | 2021-07-08 |
| AU2020358970B2 (en) | 2026-02-05 |
| US11584728B2 (en) | 2023-02-21 |
| AU2020358970A1 (en) | 2022-04-14 |
| US20240368098A1 (en) | 2024-11-07 |
| EP4038076A1 (en) | 2022-08-10 |
| IL291898A (en) | 2022-06-01 |
| WO2021067836A1 (en) | 2021-04-08 |
| US20240400529A1 (en) | 2024-12-05 |
| JP2025164962A (ja) | 2025-10-31 |
| CN114746430B (zh) | 2026-01-30 |
| JP2022551270A (ja) | 2022-12-08 |
| KR20220078644A (ko) | 2022-06-10 |
| CN114746430A (zh) | 2022-07-12 |
| US20230303506A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114746430B (zh) | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 | |
| CN115996916B (zh) | 用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法 | |
| US20250382309A1 (en) | Methods and materials for increasing transcription factor eb polypeptide levels | |
| CA3222132A1 (en) | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia | |
| US20160108035A1 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| CN114728920B (zh) | 一种沃替西汀前药及其应用 | |
| WO2023272571A1 (zh) | 2,3-环氧丁二酰衍生物的医药用途 | |
| WO2020249120A1 (zh) | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 | |
| CN113387909B (zh) | 2,3-环氧丁二酰衍生物的医药用途 | |
| HK40088188B (zh) | 用於预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法 | |
| HK40088188A (zh) | 用於预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法 | |
| CN118382435A (zh) | 12/15-脂氧合酶抑制剂 | |
| IT202400002560A1 (it) | Inibitori della proteina rock per uso nel trattamento della fibrosi polmonare |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication |